Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.
about
Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug releaseDecreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1.Elevated phospholipase A2 activities in plasma samples from multiple cancers.Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer modelCalcium-independent phospholipases A2 and their roles in biological processes and diseases.Anti-inflammatory trends of new benzimidazole derivatives.Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer.The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells.The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells.Emerging roles of lipid metabolism in cancer metastasis.Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).Interfacing materials science and biology for drug carrier design.Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS).Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.Hints on ATGL implications in cancer: beyond bioenergetic clues.
P2860
Q28547031-18736D5F-BD62-43B4-8A3B-D413393FA775Q30300375-384BBF40-F132-4D82-A1E0-52C0651BF979Q34602974-E7A2DD3C-63B4-4ACE-B2FA-4505BB0A1599Q35058009-BF92C6C5-9658-4378-9B84-6CD543B84499Q35948220-F24421AD-994B-4CFC-8F68-D9E244BC9784Q35994344-3194044E-0250-45F8-8BB4-F372ACF8DE0EQ36139722-5E3E6153-1F62-407E-A7BB-238174D82B42Q36820509-B9F359EA-6960-440D-9A08-CD86AAFB07A9Q36847992-E20141C5-5E17-4972-ADD6-017C3C7FCF98Q37711207-FD4B0534-C529-4B5E-AD48-5A254520569CQ37747513-224D3058-E55C-439C-A18A-FDB3F3E41EDAQ38072094-72A26D79-0D8E-4E06-9CDE-F43F738919DEQ38366527-B075B555-EA74-4B56-9580-B9089FFE4729Q41064033-3A8DC008-0796-4CFB-8010-49386FC53825Q52316523-A64490DE-002B-4500-98FB-14A790BC4651Q52655121-FB987F10-3EC6-489B-840F-297C630A1B62Q52689159-80C719BC-BB6C-48C3-84FA-49DAA9B0BAD7
P2860
Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Elevated and secreted phosphol ...... man epithelial ovarian cancer.
@ast
Elevated and secreted phosphol ...... man epithelial ovarian cancer.
@en
type
label
Elevated and secreted phosphol ...... man epithelial ovarian cancer.
@ast
Elevated and secreted phosphol ...... man epithelial ovarian cancer.
@en
prefLabel
Elevated and secreted phosphol ...... man epithelial ovarian cancer.
@ast
Elevated and secreted phosphol ...... man epithelial ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
Elevated and secreted phosphol ...... uman epithelial ovarian cancer
@en
P2093
Ali Hassan Hamed
Frederick B Stehman
Giuseppe Del Priore
Jeanne M Schilder
Qingchun Cai
Zhenwen Zhao
P2860
P304
P356
10.1096/FJ.12-207597
P407
P577
2012-07-05T00:00:00Z